Drugs for discoid lupus erythematosus

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2017, Pages

  Jessop, Sue ^a   Whitelaw, David A ^b   Grainge, Matthew J ^c   Jayasekera, Prativa ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d Broadgreen Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; ETRETIN; FLUOCINONIDE; HYDROCORTISONE; HYDROXYCHLOROQUINE; PIMECROLIMUS; PLACEBO; SALBUTAMOL; TACROLIMUS; TRIACYLGLYCEROL; CALCINEURIN INHIBITOR; DERMATOLOGICAL AGENT;

ACNE; BIBLIOGRAPHIC DATABASE; BURNING SENSATION; CHAPPED LIPS; COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; CORTICOSTEROID THERAPY; CREAM; DISCOID LUPUS ERYTHEMATOSUS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; ERYTHEMA; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HUMAN; MEDLINE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SIDE EFFECT; SKIN DEFECT; SKIN IRRITATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; LUPUS ERYTHEMATOSUS, DISCOID; META ANALYSIS;

ACITRETIN; ALBUTEROL; CALCINEURIN INHIBITORS; DERMATOLOGIC AGENTS; FLUOCINONIDE; HUMANS; HYDROCORTISONE; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, DISCOID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 85018782523     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002954.pub3     Document Type: Review

References (91)

1. Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clinical and Experimental Dermatology 2009;34(7):776-80. [PUBMED: 19456797]2944926
2. Jemec GB, Ullman S, Goodfield M, Bygum A, Olesen AB, Berth-Jones J, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology 2009;161(6):1365-70. [PUBMED: 19681862]2944928
3. Kuhn A, Gensch K, Haust M, Schneider SW, Bonsmann G, Gaebelein-Wissing N, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. Journal of the American Academy of Dermatology 2011;65(1):54-64. [PUBMED: 21501887]2944930
4. Roenigk HH, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner 1980;25(3):281-5. [PUBMED: 6987043]2944932
5. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology 1992;127(5):513-8. [PUBMED: 1467292]2944934
6. Avgerinou G, Papafragkaki DK, Nasiopoulou A, Arapaki A, Katsambas A, Stavropoulos PG. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. Journal of the European Academy of Dermatology and Venereology : JEADV 2012;26(6):762-7. [PUBMED: 21707772]2944936
7. Bezerra EL, Vilar MJ, de Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis and Rheumatism 2005;52(10):3073-8. [PUBMED: 16200586]2944938
8. Bjornberg A, Hellgren L. Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment. British Journal of Dermatology 1963;75:156-60. [PUBMED: 13971327]2944940
9. Furie RA, Leon G, Thomas M, Petrie MA, Chu AD, Hislop C, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Annals of the Rheumatic Diseases 2015;74(9):1667-75. [PUBMED: 24748629]5572752
10. Furie R, Das M, Li D, Smythe S, Mathura E, Becker P. Repository corticotropin injection (H.P. acthar gel) attenuates disease activity in patients with persistently active systemic lupus erythematosus (SLE) requiring corticosteroids. Arthritis and Rheumatology 2015;67:no pagination. [CENTRAL: CN-01162652; EMBASE: 72094616]5572754
11. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. Journal of the American Academy of Dermatology 2011;65(4):717-21. [PUBMED: 21641078]2944942
12. Islam NM, Hossain M, Haq SA, Alam NM, Ten Klooster PM, Rasker JJ. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. International Journal of Rheumatic Diseases 2012;15(1):62-8. [PUBMED: 22324948]5572756
13. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study. Annals of Rheumatic Diseases 2016;75(11):1909-16. [PUBMED: 27009916]5572758
14. Kraak JH, van Ketel W, Prakken JR, Van Zwet W. The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial. Dermatologica 1965;130:293-305. [PUBMED: 14333636]2944944
15. Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. Journal of the American Academy of Dermatology 2011;64(1):37-48. [PUBMED: 21167404]5572760
16. Kuhn A, Landmann A, Patsinakidis N, Ruland V, Nozinic S, Perusquia Ortiz AM, et al. Fumaric acid ester treatment in cutaneous lupus erythematosus (SLE): a prospective, open-label, phase II pilot study. Lupus 2016;25(12):1357-64. [PUBMED: 27147621]5572762
17. Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clinical and Experimental Dermatology 2010;35(1):27-30. [PUBMED: 19549244]5572764
18. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases 2012;71(11):1833-8. [PUBMED: 22550315]2944946
19. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2010;62(10):3077-87. [PUBMED: 20533545]2944948
20. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis and Rheumatism 2010;62(1):222-33. [PUBMED: 20039413]2944952
21. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Annals of the Rheumatic Diseases 2011;70(11):1905-13. [PUBMED: 21798883]2944950
22. Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. Journal of Rheumatology 2000;27(6):1429-33. [PUBMED: 10852265]5572766
23. Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis and Rheumatism 2013;65(10):2661-71. [PUBMED: 23896980]2944954
24. Thivolet J, Nicolas JF, Kanitakis J, Lyonnet S, Chouvet B. Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. British Journal of Dermatology 1990;122(3):405-9. [PUBMED: 2182099]5572768
25. Tzung TY, Liu YS, Chang HW. Tacrolimus vs clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. British Journal of Dermatology 2007;156(1):163-201. 2944956
26. Wang X, Zhang L, Luo J, Wu Z, Mei Y, Wang Y, et al. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized controlled clinical trial. Journal of Clinical Pharmacology 2015;55(11):1221-8. [PUBMED: 25951426]2944958
27. Yokogawa N, Takahashi T, Sato T, Yokota N. A double-blind, randomized, parallel-group study of hydroxychloroquine on cutaneous lupus erythematosus in Japan. Arthritis and Rheumatology 2015;67:no pagination. [CENTRAL: CN-01162609; EMBASE: 72095665]5572770
28. Zhong LLD, Bian ZX, Gu JH, Zhou X, Tian Y, Mao JC, et al. Chinese herbal medicine (Zi shen ging) for mild to moderate systemic lupus erythematosus: A pilot prospective single-blinded randomised controlled study. Evidence-based Complementary and Alternative Medicine : ECAM 2013;2013:327245. [CENTRAL: CN-00906171; EMBASE: 2013362297]5572772
29. NCT00001680. A pilot trial of topical thalidomide for the management of chronic discoid lupus erythematosus. clinicaltrials.gov/ct2/show/NCT00001680 date first received: 3 November 1999. 5572774
30. NCT00222183. Cutaneous lupus erythematosus and elidel. clinicaltrials.gov/ct2/show/NCT00222183 date first received: 19 September 2005. 5572776
31. NCT00625157. Efficacy and safety of ASF-1096 cream 0.5% in the treatment of discoid lupus erythematosus (DLE) lesions (2). clinicaltrials.gov/ct2/show/NCT00625157 date first received: 20 February 2008. 5572778
32. NCT00625521. Efficacy and safety of ASF-1096 cream 0.5% in the treatment of discoid lupus erythematosus (DLE) lesions. clinicaltrials.gov/ct2/show/NCT00625521 date first received: 20 February 2008. 5572780
33. NCT01164917. Safety study of AMG 811 in subjects with discoid lupus erythematosus. clinicaltrials.gov/ct2/show/NCT01164917 date first received: 15 July 2010. 5572782
34. NCT01300208. To evaluate the preliminary safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CC-11050 in subjects with discoid lupus erythematosus and subacute cutaneous lupus erythematosus. clinicaltrials.gov/ct2/show/NCT01300208 date first received: 18 October 2010. 5572784
35. NCT01407679. Efficacy and safety of oral alitretinoin (Toctino®) in the treatment of patients with cutaneous lupus erythematosus (AliCLE). clinicaltrials.gov/ct2/show/NCT01407679 date first received: 1 August 2011. 5572786
36. NCT01597050. Safety and efficacy of topical R333 in patients with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) lesions (SKINDLE). clinicaltrials.gov/ct2/show/NCT01597050 date first received: 9 May 2012. 5572788
37. Pothinamthong P, Janjumratsang P. A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. Journal of the Medical Association of Thailand= Chotmaihet Thangphaet 2012;95(7):933-40. [PUBMED: 22919989]2944960
38. NCT02927457. Safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of GSK2646264 in cutaneous lupus erythematosus patients [A double-blind (sponsor unblinded) study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of repeat dosing of GSK2646264 in cutaneous lupus erythematosus patients]. clinicaltrials.gov/ct2/show/NCT02927457 Date first received: 30 August 2016. 5572790
39. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. Journal of Investigative Dermatology 2005;125(5):889-94. [PUBMED: 16297185]
40. Artuz F, Lenk N, Deniz N, Alli N. Efficacy of sulphasalazine in discoid lupus erythematosus. International Journal of Dermatology 1996;35(10):746-8. [PUBMED: 8891833]
41. Brodthagen H. Hydroxychloroquine (Plaquenil) in the treatment of lupus erythematosus. Acta Dermato-venereologica 1959;39:233-7. [PUBMED: 13804646]
42. Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Archives of Dermatology 1982;118(6):412-6. [PUBMED: 7092253]
43. Callen JP. Management of antimalarial-refractory cutaneous lupus erythematosus. Lupus 1997;6(2):203-8. [PUBMED: 9061669]
44. Chasset F, Francès C, Barete S, Amoura Z, Arnaud l. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. Journal of the American Academy of Dermatology 2015;72(4):634-9. [PUBMED: 25648824]
45. Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. British Journal of Dermatology 1982;106(1):105-6. [PUBMED: 7059497]
46. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. British Journal of Dermatology 2012;166(3):616-23. [PUBMED: 21999437]
47. Dalziel K, Going S, Cartwright PH, Marks R, Beveridge GW, Rowell NR. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). British Journal of Dermatology 1986;115(2):211-6. [PUBMED: 3091062]
48. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-634. [PUBMED: 9310563]
49. Feldman R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994;189(4):425-7. [PUBMED: 7873836]
50. Fernandes MS, Girisha BS, Viswanathan N, Sripathi H, Noronha TM. Discoid lupus erythematosus with squamous cell carcinoma: a case report and review of the literature in Indian patients. Lupus 2015;24(14):1562-6. [PUBMED: 26251401]
51. Geamanu Panca A, Popa-Cherecheanu A, Marinescu B, Geamănu CD, Voinea LM. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. Journal of Medicine and Life 2014;7(3):322-326. [PUBMED: 25408748]
52. Goldberg R, Irving P. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2015;9(7):891-900. [PUBMED: 25915575]
53. Goldman L, Cole DP, Preston RH. Chloroquine diphosphate in treatment of discoid lupus erythematosus. Journal of the American Medical Association 1953;152(15):1428-9. [PUBMED: 13061294]
54. Goldstein E, Carey W. Discoid lupus erythematosus: successful treatment with oral methotrexate. Archives of Dermatology 1994;130(7):938-9. [PUBMED: 8024288]
55. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Archives of Dermatology 1983;119(10):812-5. [PUBMED: 6614949]
56. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
57. Jansen GT, Dillaha CJ, Honeycutt WM. Discoid lupus erythematosus. Is systemic treatment necessary?. Archives of Dermatology 1965;92(3):283-5. [PUBMED: 11851251]
58. Khandpur S, Sharma VK, Sumanth K. Topical immunomodulators in dermatology. Journal of Postgraduate Medicine 2004;50(2):131-9. [PUBMED: 15235214]
59. Kierland RR, Brunsting LA, O'Leary PA. Quinacrine hydrochloride (atabrine) in the treatment of lupus erythematosus. Archives of Dermatology and Syphilology 1953;68(6):651-9. [PUBMED: 13103808]
60. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of 60 cases of chronic discoid lupus erythematosus. British Journal of Dermatology 1983;108:461-6.
61. Kraak JH. Local treatment of chronic lupus erythematosus with triamcinolone injections [Lokale behandeling van chronische (lupus) erythematodes]. Nederlands Tijdschrift voor Geneeskunde 1964;108:1305-6. [PUBMED: 14177187]
62. Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Archives of Dermatology 2009;145(3):244-8. [PUBMED: 19289751]
63. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. Journal of Autoimmunity 2014;48-49:14-9. [PUBMED: 24486120]
64. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986;172(4):214-7. [PUBMED: 3519302]
65. Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. British Journal of Dermatology 1974;91(1):93-6. [PUBMED: 4851057]
66. Maguire A. Amodiaquine hydrochloride in the treatment of chronic discoid lupus erythematosus. Lancet 1962;1(7231):665-7. [PUBMED: 14468396]
67. Marsden CW. Fluocinolone acetonide 0.2 per cent cream - a co-operative clinical trial. British Journal of Dermatology 1968;80(9):614-7. [PUBMED: 4877599]
68. Martinez J, de Misa RF, Torrelo A, Ledo A. A low-dose intralesional interferon alfa for discoid lupus erythematosus. Journal of the American Academy of Dermatology 1992;26(3 Pt 2):494-6. [PUBMED: 1564159]
69. Naafs B, Faber WR. Thalidomide therapy. An open trial. International Journal of Dermatology 1985;24(2):131-4. [PUBMED: 2985516]
70. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. Journal of the American Academy of Dermatology 2005;53(1 Suppl 1):S17-25. [PUBMED: 15968260]
71. Okon L, Rosenbach M, Krathen M, Rose M, Propert K, Okawa J, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. Journal of American Academy of Dermatology 2014;70(3):583-4. [PUBMED: 24528907]
72. Ortiz NE, Nijhawan RI, Weinberg JM. Acitretin. Dermatologic Therapy 2013;26(5):390-9. [PUBMED: 24099069]
73. Prakken JR. Difficulty in judging the value of therapy. Observations in connection with reports on the treatment of chronic lupus erythematosus [Oorspronkelijke Stukken. Het moeilijke oordeel over de waarde van een therapie]. Nederlands Tijdschrift voor Geneeskunde 1961;105:971-6. [PUBMED: 13737707]
74. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015;23(5):231-69. [PUBMED: 26246395]
75. Rees RB, Maibach HI. Chloroquine. A review of reactions and dermatologic indications. Archives of Dermatology 1963;88:280-9. [PUBMED: 14043620]
76. Reyman F. Treatment of discoid lupus erythematosus with betametasone-valerate cream 1 percent. Dermatologica 1974;149(2):65-8. [PUBMED: 4615953]
77. Rodriguez-Castellanos MA, Barba Rubio J, Barba Gomez JF, Gonzalez Mendoza A. Phenytoin in the treatment of discoid lupus erythematosus. Archives of Dermatology 1995;131(5):620-1. [PUBMED: 7741559]
78. Rothfield NF, March C, Miescher P, McEwen C. Chronic discoid lupus erythematosus - a study of 65 patients and 65 controls. New England Journal of Medicine 1963;269:1155-61.
79. Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Archives of Dermatology 1988;124(6):897-902. [PUBMED: 2967674]
80. Schroeder M, Zouboulis CC. All-trans-retinoic acid and 13-cis-retinoic acid: pharmacokinetics and biological activity in different cell culture models of human keratinocytes. Hormone Metabolism Research 2007;39(2):136-40. [PUBMED: 17326009]
81. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. Journal of the American Academy of Dermatology 1991;24(1):49-52. [PUBMED: 1999529]
82. Smith JF. Intralesional triamcinolone as an adjunct to antimalarial drugs in the treatment of chronic discoid lupus erythematosus. British Journal of Dermatology 1962;74:350-3. [PUBMED: 13989464]
83. Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. European Journal of Clinical Pharmacology 2008;64(4):337-41. [PUBMED: 18157526]
84. Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Archives of Dermatology 1985;121(10):1323-5. [PUBMED: 4037829]
85. Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Archives of Dermatology 2007;143(7):873-7. [PUBMED: 17638731]
86. Vasquez R, Wang D, Tran QP, Adams-Huet B, Chren MM, Costner MI, et al. A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. British Journal of Dermatology 2013;168(1):145-53. [PUBMED: 22708924]
87. Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Transactions of the American Clinical and Climatological Association 2013;124:16-25. [PUBMED: 23874006]
88. Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. Journal of the European Academy of Dermatology and Venereology : JEADV 2008;22(1):1-6. [PUBMED: 18005117]
89. Zhou S, Wang F, Hsieh TC, Wu JM, Wu E. Thalidomide - a notorious sedative to a wonder anticancer drug. Current Medicinal Chemistry 2013;20(33):4102-8. [PUBMED: 23931282]
90. Jessop S, Whitelaw D, Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD002954]
91. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD002954.pub2]